Challenges and Driving Forces for Business Plans in Biobanking

Macheiner, Tanja; Huppertz, Berthold; Bayer, Michaela; Sargsyan, Karine

doi:10.1089/bio.2017.0018

Cited by 20 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, sustaining the operations of biobanks financially, operationally, and socially requires flexible solutions over time, based on the type of unit established. [9][10][11][12] Underlying the operations of a modern and professionalized biobank is the need for strong business practices, with business planning at its core. Our global survey suggests that organizations that support biobanks have increasingly recognized the need to professionalize their management, staffing, and operations.…”

Section: Discussionmentioning

confidence: 99%

Advancing Professionalization of Biobank Business Operations: A Worldwide Survey

Henderson

Goldring

Simeon-Dubach³

2019

Biopreservation and Biobanking

View full text Add to dashboard Cite

Quality specimens from biobanks are key resources to support reproducible research. Sustaining biobanks requires robust management. We recently published a pilot survey that indicated that over half the participating biobanks had business plans in place and another third were working on business planning. While the results provided a clue to the status of business planning in biobanking, it was concluded that a longer and more indepth survey and analysis were required. In April 2017, an extended survey was distributed worldwide in English, French, Chinese, German, and Spanish, through multiple channels. The survey was built using the Survey Monkey tool. Our hypothesis was that those biobanks that already have a business plan also have a more professional management structure. The questions were designed to understand more details about each biobank's business operations and communications. A total of 276 biobanks participated (China 65, France 40, United States 34, Spain 27, Germany 24, Australia 23, and rest of the world 63). About two thirds of the biobanks were established in the last 10 years. The responses provided data on the size of biobanks answering the survey, their status of business planning, and how and through what mediums they are communicating with customers. Biobanks with a business plan or preparing to have one showed a clear trend of having a customer strategy for marketing the samples and communicating with customers. No trend could be seen regarding websites and activities in social media. We confirmed our hypothesis that biobanks that have or are in the process of preparing a business plan are showing a trend toward more professional structures. In the biobanking community, the business mind-set and use of the business plan as a management tool have not quite arrived.

show abstract

Section: Discussionmentioning

confidence: 99%

Advancing Professionalization of Biobank Business Operations: A Worldwide Survey

Henderson

Goldring

Simeon-Dubach³

2019

Biopreservation and Biobanking

View full text Add to dashboard Cite

show abstract

“…Despite adopting this financial management system, the majority of biobanks are unable to fully recover their costs and have relied on the support of government policies and donations. A possible solution could be supporting biobanks mostly by local public bodies and partially by a cost recovery mechanism in order to favor efficient sustainability [68].…”

Section: Main Textmentioning

confidence: 99%

Biobanking in health care: evolution and future directions

et al. 2019

View full text Add to dashboard Cite

Background The aim of the present review is to discuss how the promising field of biobanking can support health care research strategies. As the concept has evolved over time, biobanks have grown from simple biological sample repositories to complex and dynamic units belonging to large infrastructure networks, such as the Pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). Biobanks were established to support scientific knowledge. Different professional figures with varied expertise collaborate to obtain and collect biological and clinical data from human subjects. At same time biobanks preserve the human and legal rights of each person that offers biomaterial for research. Methods A literature review was conducted in April 2019 from the online database PubMed, accessed through the Bibliosan platform. Four primary topics related to biobanking will be discussed: (i) evolution, (ii) bioethical issues, (iii) organization, and (iv) imaging. Results Most biobanks were founded as local units to support specific research projects, so they evolved in a decentralized manner. The consequence is an urgent needing for procedure harmonization regarding sample collection, processing, and storage. Considering the involvement of biomaterials obtained from human beings, different ethical issues such as the informed consent model, sample ownership, veto rights, and biobank sustainability are debated. In the face of these methodological and ethical challenges, international organizations such as BBMRI play a key role in supporting biobanking activities. Finally, a unique development is the creation of imaging biobanks that support the translation of imaging biomarkers (identified using a radiomic approach) into clinical practice by ensuring standardization of data acquisition and analysis, accredited technical validation, and transparent sharing of biological and clinical data. Conclusion Modern biobanks permit large-scale analysis for individuation of specific diseases biomarkers starting from biological or digital material (i.e., bioimages) with well-annotated clinical and biological data. These features are essential for improving personalized medical approaches, where effective biomarker identification is a critical step for disease diagnosis and prognosis.

show abstract

“…Embedding a data biobank in clinical care can ensure the collection of high-quality data. 25 The data sharing network will need to design a survey tool for COVID-19 patients and/or research coordinators to complete. All COVID-19 patients and/or the next of kin should sign an informed consent form (ICF); the next of kin should sign when applicable.…”

Section: Resultsmentioning

confidence: 99%

“…Data sharing is becoming inevitable owing to the collaborative efforts of researchers, pharmaceutical companies, and regulators. 25,26 Large-scale data analyses and the creation of comprehensive databases utilized for the hosting and exchange of genetic and clinical data has allowed researchers to learn and discover more about the pathogenetic mechanisms related to the illness in question, the overall response to drugs, and review of the cause of adverse events. 25,27 Researchers must remember that clinical trials focused on research involving infectious diseases or pandemic causing illnesses will deal with the geographic spread of patients and the high heterogeneity within the same disease (Fig.…”

Section: Resultsmentioning

confidence: 99%

Data Sharing Solutions for Biobanks for the COVID-19 Pandemic

Paul¹,

Chatterjee²

2020

Biopreservation and Biobanking

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness, which can result in high death rates. Biobanks will play a role in providing tools to examine data from those receiving treatment along with reviewing the current and long treatment outcomes associated with this novel coronavirus disease. A diverse, global network made up of laboratory scientists, clinical researchers, epidemiologists, data science teams, physicians, and so on must have a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank must be centrally managed to ensure standardized quality assurance and quality control efforts. Virtual biobanks will eliminate the need to transport samples between two locations for a specific study, minimizing the risk of contamination. It is necessary for virtual biobanks to upload imaging data from those patients diagnosed with COVID-19. Standardized, collected information will be essential in the area of discovery and validation of disease markers as well as novel therapeutic strategies. It is essential for biobanks to collect COVID-19 specimens along with corresponding clinical and demographic data from COVID-19 diagnostic testing. Because COVID-19 is an acute respiratory illness, proper collection procedures must be in place to collect respiratory samples for biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory Information Management System (LIMS) is an efficient tool to seamlessly manage a data sharing network. Data entered into LIMS will be beneficial in designing much needed clinical trials to address any unmet needs to better address clinical treatment and outcomes. The partners or entities associated with the COVID-19 data sharing network will be able to effectively communicate, view data, and images associated with their respective research interest to advance COVID-19 research and data driven, clinical care.

show abstract

Challenges and Driving Forces for Business Plans in Biobanking

Cited by 20 publications

References 16 publications

Advancing Professionalization of Biobank Business Operations: A Worldwide Survey

Advancing Professionalization of Biobank Business Operations: A Worldwide Survey

Biobanking in health care: evolution and future directions

Data Sharing Solutions for Biobanks for the COVID-19 Pandemic

Contact Info

Product

Resources

About